Randomized, Double-Blind, Placebo-Controlled Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986331 in Healthy Participants
Latest Information Update: 21 Oct 2022
At a glance
- Drugs BMS-986331 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 11 Mar 2022 Status changed from recruiting to completed.
- 26 Jun 2020 New trial record